CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
Published on August 11, 2022
BENITEC BIOPHARMA INC.
3940 Trust Way
Hayward, California 94545
August 11, 2022
VIA EDGAR
Alan Campbell
United States Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549-1004
| Re: | Benitec Biopharma Inc. |
Registration Statement on Form S-1 (File No. 333-266417)
Filed July 29, 2022, as amended August 8, 2022
Dear Mr. Campbell:
Reference is made to our letter, filed as correspondence via EDGAR on August 8, 2022, in which we requested the acceleration of the effective date of the above-referenced Registration Statement for Wednesday, August 10, 2022 at 4:00 p.m. Eastern Time, or as soon thereafter as practicable, in accordance with Rule 461 under the Securities Act of 1933, as amended. We are no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.
Should you have any questions, please contact Matt OLoughlin of Proskauer Rose LLP at 310.284.5654.
[Signature page follows]
| Very truly yours, | ||
| BENITEC BIOPHARMA INC. | ||
| By: | /s/ Dr. Jerel Banks |
|
| Name: Dr. Jerel Banks | ||
| Title: Chief Executive Officer | ||
| cc: | Matt OLoughlin, Proskauer Rose LLP |
Louis Rambo, Proskauer Rose LLP
[Signature Page to Acceleration Request]